Novaliq has developed an artificial tear product called NovaTears/EvoTears that addresses the lipid layer of the tear film. It has been successfully launched in Europe. Novaliq is also developing treatments for dry eye, glaucoma, and retinal diseases using their proprietary EyeSol technology platform. Their pipeline includes products in development, clinical trials, and regulatory review.

1. © 2016 Novaliq, confidential 1
Ophthalmology Innovation Summit
13th October 2016
Bernhard Günther, Co-Founder & CEO

2. © 2016 Novaliq, confidential 2
Innovation in Artificial Tears: NovaTears®/EvoTears®
• EvoTears® first-in-class artificial tears product addressing the lipid layer of the tearfilm
• 1 year post launch experience in Europe; approval path for US, JP
Innovation in Technology
• EyeSol® - a versatile platform technology for the front of and intraocular eye applications
• A platform for collaboration
Novaliq´s pipeline
• CyclASol® and NovaTears® Omega 3
• Upcoming developments for glaucoma and retina
Overview

3. © 2016 Novaliq, confidential 3
• Water-free, preservation free, amphiphilic eye lubricant for stabilization of the lipid layer
• Excellent spreading, small drops (10µl) , silky feeling, no blurring
• Prevents evaporation, supports oxygenation of the cornea, same refractive index as water
Innovation in Tears: NovaTears®/EvoTears®
A New Lubricant for the Lipid Layer of the Tear Film
Aqueous-deficient
Evaporative

4. © 2016 Novaliq, confidential 4
NovaTears®/EvoTears®
Successful Market Entry in Europe
Successful market launch in 10 EU countries; partnering opportunities for
other geographic regions
Priced at 19.95€ ($23.44) per bottle in the pharmacy, mid 6-digit units sold in y1
EU market entry in October 2015 under brand name “EvoTears®” (www.evotears.com)
European Partnership Agreement with Ursapharm, one of the leading EU ophthalmic players

5. © 2016 Novaliq, confidential 5
3 Different Populations
• Mild to Moderate Evaporative DED
• Meibomian Gland Dysfunction
• Severe DED due to oGvHD
Results
• NT-001 & -002: significant
improvement in signs and
symptoms
• NT-003: oGvHD - no added benefit,
but excellent safety
Safety
• No SAEs
• Only 8 AEs : Quickly disappeared
after stopping treatment
• Excellent safety and tolerability
Data (N=127) from three Prospective, Multicenter, Non-
interventional Studies

6. © 2016 Novaliq, confidential 6
EvoTears® in Europe One Year Post Launch
Buyer’s satisfaction: a 5 star product*
• Sehr gute Augentropfen!
• 1 von 1 Kunden fanden die folgende Meinung hilfreich.
Christine Müller schreibt am 07.09.2016
• gutes Produkt
• 3 von 3 Kunden fanden die folgende Meinung hilfreich.
Petra Tietz schreibt am 07.09.2016
• Augentropfen die wirklich helfen
• 5 von 5 Kunden fanden die folgende Meinung hilfreich.
monilein97 schreibt am 02.06.2016
• eine gute Entwicklung !
• 10 von 13 Kunden fanden die folgende Meinung hilfreich.
Rezensentin/Rezensent schreibt am 22.02.2016
• Das Beste!
• 25 von 28 Kunden fanden die folgende Meinung hilfreich.
Rezensentin/Rezensent schreibt am 02.12.2015
*https://www.medpex.de/testbericht/trockene-augen-augen-ohren/evotears-
augentropfen-p11213615/
Broadly recommended
 evaporative DED (NT-001)
 Meibomian Gland Dysfunction (NT-
002)
 For anterior and posterior blepharitis
(NT-002)
Future potential (clin. Studies
started)
• After cataract surgery
• With 1-day contact lenses
• After LASIK
KOL – study ophthalmologist
• “Nearly all patients asked to stay on
NovaTears® treatment after the
study“
• “We should consider NovaTears® as
THE new standard therapy for
evaporative Dry Eye Disease”

7. © 2016 Novaliq, confidential 7
NovaTears®/EvoTears®: US, JP and ROW
Registration &
Approval as
Medical Device
Clinical Studies Post Launch / Marketing
Launch JP
2018
Phase II
Registration &
Approval as RX-
Product
Post Launch /
Marketing
Launch US
2021
Clinical
Resarch &
Preclinic
Registration
&
Approval
Launch
EU
Post Launch/Marketing
Phase III
2015 2016 2017 2018 2019 2020 20212015 2016 2017 2018 2019 2020 2021
Development
NovaTears®
Omega 3
Registration &
Approval
2017
Post Launch / Marketing
NovaTears® extension of product
family
Launch 2018

8. © 2016 Novaliq, confidential 8
Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease - A Prospective,
Multicenter Noninterventional Study
Steven et al.
J Ocul Pharmacol Ther. 2015 Oct;31(8):498-503
NovaTears® as new Therapy in Dry Eye. Results from three prospective, multicenter,
non-interventional studies in different patient populations
Kaercher T.1, Steven P.2, Messmer E.M.3, Beckert M.4, Krösser S.5
Poster: TFOS, Montpellier Sep 2016
Semifluorierte Alkane als Therapie bei Meibomdrüsen-Dysfunktion
Ergebnisse einer prospektiven, multizentrischen Beobachtungsstudie
Messmer E.M.1, Kaercher T.2, Kunert K.S.3, Schrems W.4, Menzel-Severing J.4, Schrage N.5,Augustin A.J.6, Dacheva I.7, Geerling G.8, Krösser S.9,
Beckert M.10,
Poster: German Ophthalmologic Society; Berlin Oct 2016
Peer Reviewed Scientific Publications on
NovaTears®/EvoTears®:

9. © 2016 Novaliq, confidential 9
Innovation in Technology: EyeSol® Delivers Solutions to Key
Ophthalmic Challenges
1. Innovative formulations of poorly soluble drugs
Direct and clear
solutions
Suspension
2. Improved Penetration
3. Higher stability and activity
Stable in EyeSol®
formulation
Inactive in
standard
formulation
Therapeutic protein at 50°C

10. © 2016 Novaliq, confidential 10
Rx - CyclASol® is Currently Being Tested in Phase 2
Timeline
Phase 2 study design
Design:
• 4 arm randomized parallel
double masked vehicle
controlled study with two
doses of CyclASol® and open
label comparator arm
• N= 50/arm
• 2 weeks run-in, 4 month
treatment
Timeline for results
• Headline data Q1 2017
available
• Significant value inflection
point
Screening and
Run-in
with
Systane® Balance
2 weeks
CyclASol® 0.05 % BID 4 month N=50
Placebo to CyclASol® BID 4 month N=50
Restasis® BID 4 month N=50
V 1
CyclASol® 0.1 % BID 4 month N=50
Visit 0 V 2 V 3 V 4 V 5
Planning
Clinical FPFV-LPLV
Top Line
Data
CSR Start
Preparation
Phase 3
End of Phase 2
Meeting

11. © 2016 Novaliq, confidential 11
Omega 3 Fatty Acids:
• Stabilize the lipid film
• Demonstrate an anti-inflammatory effect
• Unstable in water based systems and under air
The product:
• Clear solution of 2mg/ml Omega-3 oil in an EyeSol® formulation
• Preservative free multidose units
• 1 month in-use and so far 12 month stability at ambient conditions (study on-going)
• Commercial supply chain established
Regulatory:
• Registration as medical device ongoing in Europe
• Expected launch in Europe Q4/2017
NovaTears® + Omega-3: A Long-term Stable Omega-3 Eye Drop
Formulation for Treatment of Evaporative Dry Eye Disease

12. © 2016 Novaliq, confidential 12
OTC/CE
Novaliq’s Pipeline Addresses Key Indications in
Ophthalmology
Product
EvoTears® (EU)
NovaTears® & Omega3 (EU)
NovaTears® (JP)
Dry Eye evaporative
Dry Eye moderate
Dry Eye evaporative
Rx
Product/Program
CyclASol®
Nov-03 (NovaTears®) (US)
Nov-04
Dry Eye moderate – severe
Dry Eye (evaporative,MGD)
Glaucoma
Nov-05
Nov-06
Retinal Diseases
Retinal Diseases
Research MarketRegistration(Clinical Study)
Research Market
Appro-
val
Indication
Pre-
clinic Phase I Phase II Phase III

13. © 2016 Novaliq, confidential 13
Novaliq Summary
• Innovative technology platform
• First OTC product successful in the $2bn Artificial Tears Market
• Advanced Phase 2 Study for Dry Eye underway
• Pharma collaborations via EyeSol® licensing

14. © 2016 Novaliq, confidential 14
Your contacts
Bernhard Günther
+49 6221-50259-10
bguenther@novaliq.com
Novaliq GmbH
Im Neuenheimer Feld 515
69120 Heidelberg
Germany
www.novaliq.com
Dr. Frank Löscher
+49 6221-50259-272
floescher@novaliq.com
Dr. Hartmut Voss
+49 6221-50259-285
hvoss@novaliq.com
Dr. Oliver Schlüter
+49 6221-50259-155
oschlueter@novaliq.com
Dr. Christian Roesky
+49 6221-50259-220
croesky@novaliq.com

15. © 2016 Novaliq, confidential 15